---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic burden and healthcare resource utilization. Topics: Two-year all-cause costs and resource use versus matched controls in 790 newly diagnosed US adults; First-year all-cause costs by immunoglobulin use pattern in 3409 US adults; Two-year CIDP-specific costs by treatment cohort in US commercial claims; Cost of illness and cost drivers in the United Kingdom, France, Germany, and the United States: systematic review; 5 further topics. 9 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### Two-year all-cause costs and resource use versus matched controls in 790 newly diagnosed US adults

> “This retrospective case-control analysis was conducted using data from the IQVIA Real-World Data Adjudicated Claims.”
> “The final sample comprised a total of 790 cases matched to 790 controls.”
> “Cases had 7.5x higher mean total costs ($116,330 vs. $15,586, p<0.0001).”
> “Important cost drivers were costs for outpatient ancillary, radiology and HCPCS drugs (mean $76,366 vs. $4,292) and costs for inpatient care (mean $16,357 vs. $2,862) (both p<0.0001).”
> “Among cases, CIDP therapy (inclusive of both outpatient pharmacy and medical claims) accounted for 51.2% of mean total costs.”
> “From treatment initiation to the end of the 24-month follow-up, corticosteroid patients had mean (SD) CIDP therapy costs of about $7,900 ($35,000) while IVIg patients had mean CIDP therapy costs of $165,000 ($170,000).”

Source: [Divino et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6198979/)

<a id="topic-2.2.1.8.2-2"></a>

### First-year all-cause costs by immunoglobulin use pattern in 3409 US adults

> “A retrospective cohort study was conducted using a US claims dataset (Komodo Health closed claims, Jan 2016 – Dec 2020).”
> “62% (n=1113/1803) were chronic IG users, and 38% (n=690/1803) were intermittent IG users.”
> “Based on US claims data, the economic burden for adult patients with CIDP was driven by treatment pattern, with substantial burden observed in patients receiving chronic IG.”

Source: [Guptill et al. (2024)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3895/136957)

| Measure, year 1 after index | Value |
| --- | --- |
| All-cause outpatient visits, all patients | “31.74” |
| All-cause inpatient days, patients with at least 1 visit | “2.40” |
| Mean all-cause total cost, all patients | “$105,554” |
| Mean annual all-cause total cost, chronic immunoglobulin users | “$247,456” |

Source: [Guptill et al. (2024)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3895/136957)

<a id="topic-2.2.1.8.2-3"></a>

### Two-year CIDP-specific costs by treatment cohort in US commercial claims

> “This retrospective cohort study evaluated the treatment patterns and CIDP-related healthcare costs over a 2-year follow-up period for patients with newly diagnosed CIDP who had commercial insurance, using claims data from the IMS LifeLink PharMetrics Plus Claims database between 2009 through 2014.”
> “The mean total CIDP-specific 2-year follow-up costs were highest for the cohort that received IVIG alone ($119,928) or with an additional therapy ($133,334) and lowest for patients who received active surveillance ($3723) or steroids alone ($3101).”
> “When costs by site of care were investigated, the majority of IVIG infusion costs were found to be in the home rather than in the clinic or hospital setting.”

Source: [Guptill et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6611518/)

<a id="topic-2.2.1.8.2-4"></a>

### Cost of illness and cost drivers in the United Kingdom, France, Germany, and the United States: systematic review

> “CIDP cost of illness varied across geographies, from £22,086 (2007 costs) annually per patient in the UK, through €47,823 (2017 costs) and €45,000 (2013 costs) annually per patient in France and Germany, respectively, to $116,330 (costs converted to USD 2016 values) over 2 years in the USA”
> “Similarly, in the US, drug-related costs represented 57% of total costs, followed by inpatient and outpatient hospital services (35%)”
> “In the US, the majority of IVIG infusions occurred at home (72%), followed by physician offices (16%) and outpatient hospitals (11%)”
> “In the UK, loss of productivity was estimated to cost £5815 per patient per year, and projected to cost the UK economy a total of £9.7 M per year, accounting for 26% of the total cost of illness”

Source: [Querol et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8463372/)

<a id="topic-2.2.1.8.2-5"></a>

### Quarterly societal costs and the share attributable to immunoglobulin in 108 patients in Germany

> “In total, 108 patients were recruited from 3 specialized neuroimmunological clinics.”
> “Total quarterly costs were €11,333. Direct costs contributed to 83% of total costs (€9,423), whereas indirect costs accounted for 17% (€1,910) of total costs. The cost of intravenous immunoglobulin (IVIg) was the main determinant of total costs (67%).”
> “Reduced health-related quality of life and depressive symptoms were identified as independent predictors of higher total costs.”

Source: [Mengel et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30073683/)

<a id="topic-2.2.1.8.2-6"></a>

### Hospitalizations, mobility aids, and productivity losses by disability level in 542 patients in five European countries

> “Neurologists provided data on treatment, informal care, hospitalizations, mobility aids, and home modifications for 542 patients, while lost productivity was reported by a subset of patients ( n = 199).”
> “Hospitalizations in the 12 months prior to the survey were more frequent with greater disability (mild 7.0%, moderate 14.5%, severe 21.6%; p < 0.001), as were emergency admissions (1.0, 9.9, 13.7% respectively; p < 0.001) and ICU stays (0.0, 0.7, 3.9% respectively; p = 0.001).”
> “The use of mobility aids (19.1, 56.1, 89.7% respectively) and home modifications (12.8, 45.8, 74.2% respectively) also rose significantly with severity ( p < 0.001 for both).”
> “Finally, work productivity losses among employed patients and activity impairment rose as disability increased (average percentage of productivity loss: mild 21.8%, moderate 44.0%, severe: 67.3%, p < 0.001; average daily activity impairment: mild 28.6%, moderate: 44.6%, severe: 68.1%, p < 0.001).”
> “As shown in Figure 4A , the proportion of patients employed at the time of the survey decreased with increasing disability severity (mild: 71.4%; moderate: 69.8%; severe: 39.1%; p = 0.049).”

Source: [Brackx et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13368673/)

<a id="topic-2.2.1.8.2-7"></a>

### Annual immunoglobulin costs per person and savings from cessation trials in a UK center

> “IVIg is a relatively scarce and expensive resource at a cost of £71/g, with immunomodulatory use representing £300 million per year of National Health Service (NHS) UK spending, and similar expenditure in other high income countries”
> “The median cost of IVIg was £97 705 per person/year, at a median frequency of 2.4 days/month in the day care unit (£9213 per person/year), giving a total median cost of £106 918 per person/year.”
> “The cost saving associated with successful IVIg cessation in eight individuals was £855 344 per year, including IVIg spend and daycare unit costs.”

Source: [Koay et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11836592/)

<a id="topic-2.2.1.8.2-8"></a>

### Annual cost of immunoglobulin maintenance treatment by route of administration in Spain

> “A cost-analysis model based on a decision tree was developed to evaluate the annual cost per patient treated with each immunoglobulin from a societal perspective.”
> “The annual cost for a patient with CIDP receiving maintenance treatment was €109,212.67 with IVIG, €98,161.97 with c-SCIG, and €98,191.37 with f-SCIG.”
> “The main driver of the difference between SCIG and IVIG cost was treatment administration (−€10,705.78).”

Source: [de Pedro et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13000016/)

<a id="topic-2.2.1.8.2-9"></a>

### Annual health plan paid cost per patient and share attributable to immunoglobulin in US commercial health plans, 2011

> “The most prescribed therapies were intravenous immunoglobulin (IVIg) (26% of patients), gabapentin (26%), and prednisone (16%).”
> “The annual health plan paid cost was $56,953. Pharmacy cost was the major cost driver (57% of the total), and IVIg totaled 90% of the pharmacy costs.”

Source: [Guptill et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24639235/)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
